Hodgkin’s disease (HD) is a lymphoid malignancy characterized by infrequent malignant cells surrounded by abundant inflammatory cells. In this study, we examined the potential contribution of chemokines to inflammatory cell recruitment in different subtypes of HD. Chemokines are small proteins that are active as chemoattractants and regulators of cell activation. We found that HD tissues generally express higher levels of interferon-γ–inducible protein-10 (IP-10), Mig, RANTES, macrophage inflammatory protein-1 (MIP-1), and eotaxin, but not macrophage-derived chemotactic factor (MDC), than tissues from lymphoid hyperplasia (LH). Within HD subtypes, expression of IP-10 and Mig was highest in the mixed cellularity (MC) subtype, whereas expression of eotaxin and MDC was highest in the nodular sclerosis (NS) subtype. A significant direct correlation was detected between evidence of Epstein-Barr virus (EBV) infection in the neoplastic cells and levels of expression of IP-10, RANTES, and MIP-1. Levels of eotaxin expression correlated directly with the extent of tissue eosinophilia. By immunohistochemistry, IP-10, Mig, and eotaxin proteins localized in the malignant Reed-Sternberg (RS) cells and their variants, and to some surrounding inflammatory cells. Eotaxin was also detected in fibroblasts and smooth muscle cells of vessels. These results provide evidence of high level chemokine expression in HD tissues and suggest that chemokines may play an important role in the recruitment of inflammatory cell infiltrates into tissues involved by HD.

HODGKIN’S DISEASE (HD) is a lymphoid malignancy characterized by infrequent malignant Reed-Sternberg (RS) and Hodgkin’s cells within an environment of nonmalignant cells, including T cells, macrophages, fibroblasts, plasma cells, eosinophils, and neutrophils. The occurrence of relatively rare neoplastic cells within a context of reactive cells has suggested that a prominent local inflammatory response to the RS and Hodgkin’s cells is a key feature of this malignancy. The intense inflammation could reflect an insufficient and/or ineffective antitumor response that may itself contribute to the disease.

A number of studies have documented that HD is a neoplasia associated with abnormal cytokine production.1-3 Excess production of the inhibitory cytokine, interleukin (IL)-10, may contribute to reduced T-cell immunity, and abnormally high levels of IL-6, IL-1, and tumor necrosis factor (TNF)-α may account for some of the constitutional symptoms that are commonly associated with HD.1,4 Other aspects of HD, including peripheral blood eosinophilia, plasmacytosis, and thrombocytosis could also be contributed by abnormally high cytokine levels of IL-3 and IL-5, IL-6 and IL-11, respectively.4 However, systemic cytokine imbalances are unlikely to explain the characteristic cellular infiltrates that surround the malignant cells. Rather, the nature of cellular infiltrates in HD tissues could be explained on the basis of certain chemokines being locally produced promoting selective cell migration.

Recent studies in an athymic mouse model have described a host response to Epstein-Barr virus (EBV)-immortalized cells and identified two mediators of this response as the CXC chemokines IP-10 and Mig.5-7 Increased production of IP-10 and Mig was also identified in the EBV-positive lymphomatous tissues representative of lymphomatoid granulomatosis and nasal or nasal-type T/natural killer (NK) cell lymphoma.8 Chemokines are members of a family of small proteins that are active as chemoattractants and cell activators.9 Some members of this family have received considerable attention because they display selectivity of cell targets and receptors. This selectivity has suggested the possibility that the cellular composition of inflammatory responses may, in part, be a function of the chemokines being produced at a site. Except for preliminary results on expression of IL-8, a neutrophil chemoattractant and activating factor, and the related monocyte chemotactic peptide-1 (MCP-1) that attracts and activates monocytes, there is limited information on the involvement of other chemokines in the pathogenesis of the cellular infiltrates that characterize HD and its histologic subtypes.1 3 

In this study, we examined the potential contribution of chemokines to the inflammatory response in HD tissues and the various disease subtypes. In particular, we have focused on the CXC chemokines, IP-10 and Mig, that are chemoattractant for T and NK cells and their relationship to positivity with EBV, and the CC chemokine eotaxin that is a chemoattractant for eosinophils and its relationship to tissue eosinophilia.

Case selection.

Lymph node biopsies were retrieved from the consultation files of one of us (E.S.J.) in the Hematopathology Section, Laboratory of Pathology, National Cancer Institute, National Institutes of Health (NIH). Cases included: HD, 20 cases, further subclassified as mixed cellularity (MC), 6 cases; nodular sclerosis (NS), 9 cases; nodular lymphocyte predominant (NLP), 5 cases; and 6 control cases of reactive lymphoid hyperplasia (RLH). All patients were human immunodeficiency virus (HIV) negative. HD cases were classified according to the Revised European American Lymphoma (REAL) classification.10 By immunohistochemistry, the neoplastic cells (RS, Hodgkin’s or “popcorn cells”) stained positively with LeuM1 (CD15) and BerH2 (CD30) in the MC and NS subtypes and positively with L26 (CD20) in the NLP subtype. The extent of tissue eosinophilia was determined by two of us (J.T.F. and E.S.J.) by counting the number of eosinophils present in at least 20 separate high powered fields using an ocular grid eyepiece and calculating the mean number of eosinophils per sample. Within a given biopsy section, we selected areas involved by HD containing the greatest proportion of eosinophils. Samples were classified as having 0 eosinophils/high powered field, 1 to 25 eosinophils/high powered field, or >25 eosinophils/high powered field.

EBV in situ hybridization.

In situ hybridization used an EBV probe specific for EBV-encoded small RNAs (EBER), as described previously11 using an automated system (Ventana Medical System, Inc, Tuscon, AZ).

Reverse transcriptase-mediated polymerase chain reaction (RT-PCR).

RNA extraction from paraffin-embedded tissue was performed as previously described.8 Briefly, 6 to 10 20-μm paraffin sections were deparaffinized three times in xylene (with heating at 55°C for 10 minutes), twice in 100% ethanol, and twice in 70% ethanol. Sections were suspended in 1 mL extraction buffer (10 mmol/L NaCl, 50 mmol/L Tris-HCL, pH 7.4, 20 mmol/L EDTA, 1% sodium dodecyl sulfate [SDS]) at 55°C overnight with 500 μg/μL proteinase K. After addition of 1 mL of RNA Trizol (GIBCO/BRL, Life Technologies, Gaithersburg, MD) and 200 μL of chloroform, followed by centrifugation, the aqueous phase was combined with an equal volume of isopropanol. The precipitated pellet was washed with 70% ethanol and resuspended in diethylpyrocarbonate (DEPC)-treated water. RT-PCR applied to highly degraded RNA obtained from paraffin-embedded tissues was performed as previously described.8 Briefly, RNA samples were DNAse treated (GIBCO/BRL, Life Technologies), then subjected to an initial assay for amplifiable contaminating genomic DNA using primers specific for glyceradehyde-3-phosphate dehydrogenase (G3PDH) mRNA. Positive samples were retreated with DNase, negative samples (2 to 5 μg) were reverse transcribed using an RNase H-RT (Superscript; GIBCO/BRL, Life Technologies). The resultant cDNA (25 to 100 ng) was amplified as previously described.8 The amount of cDNA used for each amplification reaction was based for each sample on the results of PCR for G3PDH showing equivalent amounts of product amplified from all samples. The selection of G3PDH was based on the observation that G3PDH mRNA is not known to vary in human tisses depending on disease status. Primers, listed in Table 1, were designed for amplification of short amplicons (80 to 130 bp) from highly degraded RNA and spanned at least one splice junction. Genomic DNA could be distinguished from mRNA or cDNA. Amplifications were performed in a thermocycler (Stratagene Robocycler, La Jolla, CA) adding 1.25 U Taq polymerase (GIBCO/BRL) after heating at 94°C for 3 minutes (“Hot Start”); followed by a predetermined number of amplification cycles (94°C, 45 seconds; primer annealing temperature as specified in Table 1 and extension at 72°C); and maintained at 4°C until analysis. The number of amplification cycles was determined experimentally for each primer pair to fit the linear part of the sigmoid curve reflecting the relationship between the number of amplification cycles and amount of PCR product. PCR products were detected by quantitating incorporated32P-labeled nucleotides [α-32P]deoxycytidine triphosphate (dCTP) (specific activity of ≈ 3,000 Ci/mmol) obtained from Amersham, Inc (Arlington Heights, IL). The entire amplification reaction (50 μL) was analyzed by electrophoresis on 8% acrylamide (Long Ranger; AT Biochem, Malvern, PA) Tris-borate EDTA gels (polyacrylamide gel electrophoresis [PAGE]), followed by autoradiography and quantitation by phosphorimage analysis using ImageQuantTM v3.3 software (Molecular Dynamics, Sunnyvale, CA). Band integrations were obtained as the sum of values for all pixels after subtraction of background (areas around each sample). Integrated values for each sample were then normalized for the results of parallel RT-PCR amplification for G3PDH expressed as pixels. The results of RT-PCR analysis are presented as absolute numbers of normalized arbitrary units (pixels)/sample. The ability of the RT-PCR assay to detect quantitative differences in mRNA for each gene product was assessed in experiments where the input cDNA derived from RNA extracted from paraffin-embedded tissues was first serially diluted (100 ng to 1 ng) and then subjected to PCR amplification. Using paraffin-embedded tissues positive for a given gene product along with appropriate negative controls, we verified that the intensity of the PCR product correlated with the dilution of input cDNA in the range used for PCR (25 to 100 ng). Variability of results from different experiments was minimized by use of standard control RNA preparations in parallel PCR. Experiments were considered evaluable only if standard control PCR results were within 15% of the mean.

Table 1.

PCR Primers and Conditions

PCR Product Genbank Accession Primer Sequence (5′; 3′) Cycle No. Anneal Temperature (°C)
Mig X72755S60728 TTCCTCTTGGGCATCATCTTGCTG; GGTCTTTCAAGGATTGTAGGTGGA  35 59  
IP-10  X02530M17752 GGAACCTCCAGTCTCAGCACC; GCGTACGGTTCTAGAGAGAGGTAC  35  59 
IFN-γ  V00536 AO4665  GGACCCATATGTAAAAGAAGCAGA; TGTCACTCTCCTCTTTCCAATTCT  35 57  
TNF-α  M10988 TCAGCTTGAGGGTTTGCTACAA; TCTGGCCCAGGCAGTCAGATC  35  59  
RANTES  M21121 GGCACGCCTCGCTGTCATCCTCA; CTTGATGTGGGCACGGGGCAGTG  35  65 
MIP-1α  M25315 CTCTGCACCATGGCTCTCTGCAAC; TGTGGAATCTGCCGGGAGGTGTAG  35  62  
Eotaxin  D49372 ACATGAAGGTCTCCGCAGCACTTC; TTGGCCAGGTTAAAGCAGCAGGTG  35  61 
MDC  U83171 ATGGCTCGCCTACAGACTGCACTC; CACGGCAGCAGACGCTGTCTTCCA  35  62  
G3PDH  M33197M32599 GCCACATCGCTAAGACACCATGGG; CCTGGTGACCAGGCGCCCAAT  35 59 
PCR Product Genbank Accession Primer Sequence (5′; 3′) Cycle No. Anneal Temperature (°C)
Mig X72755S60728 TTCCTCTTGGGCATCATCTTGCTG; GGTCTTTCAAGGATTGTAGGTGGA  35 59  
IP-10  X02530M17752 GGAACCTCCAGTCTCAGCACC; GCGTACGGTTCTAGAGAGAGGTAC  35  59 
IFN-γ  V00536 AO4665  GGACCCATATGTAAAAGAAGCAGA; TGTCACTCTCCTCTTTCCAATTCT  35 57  
TNF-α  M10988 TCAGCTTGAGGGTTTGCTACAA; TCTGGCCCAGGCAGTCAGATC  35  59  
RANTES  M21121 GGCACGCCTCGCTGTCATCCTCA; CTTGATGTGGGCACGGGGCAGTG  35  65 
MIP-1α  M25315 CTCTGCACCATGGCTCTCTGCAAC; TGTGGAATCTGCCGGGAGGTGTAG  35  62  
Eotaxin  D49372 ACATGAAGGTCTCCGCAGCACTTC; TTGGCCAGGTTAAAGCAGCAGGTG  35  61 
MDC  U83171 ATGGCTCGCCTACAGACTGCACTC; CACGGCAGCAGACGCTGTCTTCCA  35  62  
G3PDH  M33197M32599 GCCACATCGCTAAGACACCATGGG; CCTGGTGACCAGGCGCCCAAT  35 59 

Abbreviations: Mig, monokine induced by interferon-γ; IP-10, interferon-γ–inducible protein-10; IFN-γ, interferon-γ; TNF-α, tumor necrosis factor-α; RANTES, regulated uponactivation, normal T expressed andsecreted; MIP1-α, macrophage inflammatory protein 1-α; MDC, macrophage-derived chemotactic factor; G3PDH, glyceraldehyde-3-phosphate dehydrogenase.

IP-10, Mig, and eotaxin immunohistochemistry.

Reactions were performed as previously described.8 Briefly, to enhance chemokine detection, tissue sections were first treated with a Target Retrieval Solution (DAKO Corp, Carpenteria, CA) in a microwave pressure cooker (Nordic Ware, Minneapolis, MN) at maximum power (800 W) for 8 minutes, then washed in 0.05 mol/L Tris-HCL saline (TBS, pH 7.6 containing 5% fetal calf serum [FCS]; GIBCO Laboratories, Grand Island, NY) for 30 minutes. The slides were incubated with primary antibodies including rabbit antihuman IP-10 purified antibody (1:1,000 dilution, Peprotech Inc, Rocky Hill, NJ), or rabbit antihuman Mig antiserum (1:5,000 dilution, a generous gift from Dr Joshua Farber, National Institute of Allergy and Infectious Diseases [NIAID], NIH) overnight at room temperature, or rabbit antihuman eotaxin antiserum (1:40 dilution, Peprotech Inc) for 30 minutes at room temperature. Antibody dilutions were made with TBS containing 10% FCS and 0.1% (wt/vol) NaN3. Bound antibodies were detected with a biotin-conjugated universal secondary antibody formulation, which recognizes rabbit immunoglobulins (Ventana Medical Systems). After addition of an avidin-horseradish peroxidase conjugate, the enzyme complex was visualized with 3,3’-diaminobenzdine tetrachloride (DAB) and copper sulfate.

Statistical analysis.

Geometric means, standard errors of the mean (SEM) used conventional formulas. The significance of group differences was calculated by the Wilcoxon rank sums test. The significance of nonparametric measures of association was calculated by the Kendall Tau test.

To assess cytokine and chemokine gene expression in HD tissues, total RNA was extracted from formalin-fixed, paraffin-embedded tissues (total number, 20) involved by HD of the MC (6 cases), NS (9 cases), and NLP (5 cases) subtypes. In situ hybridization for the EBV-encoded small RNAs (EBERs) showed neoplastic cells latently infected with EBV in 7 of 19 cases (no tissue remained in the paraffin block from one case). Selected patient and tissue information is listed in Table 2. Control RNA was extracted from formalin-fixed, paraffin-embedded tissues representative of reactive lymphoid hyperplasia (RLH, 6 cases). All control cases of RLH tested EBV-negative by EBER-1 in situ hybridization. Using a semiquantitative RT-PCR analysis of tissues involved by HD, we found the PCR products for interferon (IFN)-γ, TNF-α, and for the chemokines Mig, IP-10, RANTES, MIP-1α, MDC, and eotaxin to be amplified at variable levels (representative results shown in Fig 1). When compared with RLH tissues (Fig 2), levels of expression of IP-10, Mig, RANTES, MIP-1α, and eotaxin were significantly higher in HD tissues (IP-10, P = .04; Mig,P = .01; RANTES, P = .03; MIP-1α, P = .04; eotaxin, P = .04). In contrast, MDC expression levels were similar in the two groups (P = .73).

Table 2.

HD Patients, Tissue EBV Status, and Extent of Eosinophilia

Patient Age/Sex Site EBV* in Neoplastic CellsExtent of Eosinophilia
MC  
 1  69/F  LN  1  
 2  46/M  Mediastinum  +  0  
 3  45/M LN, R scalene  +  1  
 4  58/F  LN, retroperit  0  
 5  76/F  LN, L cervical  +  1  
 6  84/F LN, cervical  −  0  
NS  
 1  45/F  R neck  1  
 2  78/M  Pelvic mass  +  2  
 3  36/F LN, R cervical  −  1  
 4  27/F  LN, L cervical −  1  
 5  28/F  Mediastinum  −  2  
 6 54/F  LN, R inguinal  −  0  
 7  45/M Pericardium  −  1  
 8  38/M  Mediastinum  − 2  
 9  27/M  LN, R cervical  NT  2  
NLP  
 1 23/M  LN, L inguinal  −  0  
 2  9/M  L neck mass  −  0  
 3  57/M  LN, L neck  −  
 4  42/F  LN, L neck  −  0  
 5  49/F  LN, R inguinal  −  0  
Lymphoid Hyperplasia 
 1  59/F  LN, neck  −  0  
 2  38/F  LN, inguinal  −  0  
 3  12/M  LN, neck  −  
 4  57/F  LN, cervical  −  0  
 5  40/M LN, cervical  −  0  
 6  16/M  LN, cervical −  
Patient Age/Sex Site EBV* in Neoplastic CellsExtent of Eosinophilia
MC  
 1  69/F  LN  1  
 2  46/M  Mediastinum  +  0  
 3  45/M LN, R scalene  +  1  
 4  58/F  LN, retroperit  0  
 5  76/F  LN, L cervical  +  1  
 6  84/F LN, cervical  −  0  
NS  
 1  45/F  R neck  1  
 2  78/M  Pelvic mass  +  2  
 3  36/F LN, R cervical  −  1  
 4  27/F  LN, L cervical −  1  
 5  28/F  Mediastinum  −  2  
 6 54/F  LN, R inguinal  −  0  
 7  45/M Pericardium  −  1  
 8  38/M  Mediastinum  − 2  
 9  27/M  LN, R cervical  NT  2  
NLP  
 1 23/M  LN, L inguinal  −  0  
 2  9/M  L neck mass  −  0  
 3  57/M  LN, L neck  −  
 4  42/F  LN, L neck  −  0  
 5  49/F  LN, R inguinal  −  0  
Lymphoid Hyperplasia 
 1  59/F  LN, neck  −  0  
 2  38/F  LN, inguinal  −  0  
 3  12/M  LN, neck  −  
 4  57/F  LN, cervical  −  0  
 5  40/M LN, cervical  −  0  
 6  16/M  LN, cervical −  

Abbreviations: NT, no tissue available; retroperit, retroperitoneal.

*

EBER1 expression was assessed by in situ hybridization.

Grade of tissue eosinophilia was determined; 0 = no eosinophils/high powered field; 1 = 1-25 eosinophils/high powered field; 2 = >25 eosinophils/high powered field).

Fig. 1.

Patterns of cytokine and chemokine mRNA expression in HD tissues shown by RT-PCR analysis. Total cellular RNA, extracted from paraffin-embedded tissues representative of HD MC, NS, NLP, and of lymphoid hyperplasia, was subjected to RT-PCR analysis using appropriately designed primers.

Fig. 1.

Patterns of cytokine and chemokine mRNA expression in HD tissues shown by RT-PCR analysis. Total cellular RNA, extracted from paraffin-embedded tissues representative of HD MC, NS, NLP, and of lymphoid hyperplasia, was subjected to RT-PCR analysis using appropriately designed primers.

Close modal
Fig. 2.

Levels of chemokine mRNA expression in HD tissues and lymphoid hyperplasia. Total cellular RNA, extracted from paraffin-embedded tissues diagnosed with HD (▪) and lymphoid hyperplasia (□) was subjected to semiquantitative RT-PCR. After normalization to a standard RNA preparation and to G3PDH, the results of phosphorimage analysis are shown and plotted logarithmically as the geometric means (x/÷ SEM) of normalized arbitrary units (pixels)/group for each respective chemokine. SEMs were too small to be distinguished from the mean.

Fig. 2.

Levels of chemokine mRNA expression in HD tissues and lymphoid hyperplasia. Total cellular RNA, extracted from paraffin-embedded tissues diagnosed with HD (▪) and lymphoid hyperplasia (□) was subjected to semiquantitative RT-PCR. After normalization to a standard RNA preparation and to G3PDH, the results of phosphorimage analysis are shown and plotted logarithmically as the geometric means (x/÷ SEM) of normalized arbitrary units (pixels)/group for each respective chemokine. SEMs were too small to be distinguished from the mean.

Close modal

The variability in levels of cytokine and chemokine gene expression in HD tissues prompted us to examine whether the presence of EBV in the malignant cells and/or the histological subtype might correlate with certain patterns of cytokine and/or chemokine gene expression. Previous experiments had demonstrated that, in athymic mice, EBV-infected human lymphoblastoid cells elicit a characteristic cytokine and chemokine response, including elevated expression of murine IFN-γ, IL-6, TNF-α, IP-10, and Mig.6 7 By contrast, EBV-negative Burkitt cells generally do not elicit this response. We found mean tissue levels of IP-10, Mig, RANTES, and MIP-1α expression to be higher in EBV-positive than in EBV-negative HD tissues (Fig 3), and this difference was significant for IP-10 (P = .05, Wilcoxon rank sums test), RANTES (P = .005), and MIP-1α, (P = .02) and approached significance for Mig (P = .1). By contrast, expression levels of MDC and eotaxin were similar (P= .97 in both cases) in EBV-positive and negative HD tissues (Fig3). Thus, the presence of EBV in HD tissues is generally associated with higher level expression of certain chemokines, including IP-10, Mig, RANTES, and MIP-1α.

Fig. 3.

Levels of chemokine mRNA expression in EBV-positive (▪) and EBV-negative (□) HD tissues. Total cellular RNA, extracted from paraffin-embedded tissues diagnosed with MC, NS, or NLP HD was subjected to semiquantitative RT-PCR. After normalization to a standard RNA preparation and to G3PDH, the results of phosphorimage analysis are shown and plotted logarithmically as the geometric means (x/÷ SEM) of normalized arbitrary units (pixels)/group for each respective chemokine. SEMs were too small to be distinguished from the mean.

Fig. 3.

Levels of chemokine mRNA expression in EBV-positive (▪) and EBV-negative (□) HD tissues. Total cellular RNA, extracted from paraffin-embedded tissues diagnosed with MC, NS, or NLP HD was subjected to semiquantitative RT-PCR. After normalization to a standard RNA preparation and to G3PDH, the results of phosphorimage analysis are shown and plotted logarithmically as the geometric means (x/÷ SEM) of normalized arbitrary units (pixels)/group for each respective chemokine. SEMs were too small to be distinguished from the mean.

Close modal

Because EBV infection is most frequent in the MC disease subtype (60% to 70% positive) of HD as compared with the NS (approximately 40% positive) and NLP (usually EBV-negative) subtypes,10 12this group might also display increased expression of those EBV-associated cytokines and chemokines compared with the other disease subtypes. The seven EBV-positive HD cases studied here were classified as belonging to the MC subtype in five cases and to the NS subtype in two cases. When analyzed by subtype (Table3), the MC group expressed geometric mean levels of IP-10, Mig, and MIP-1α that were higher compared with the other subgroups, and this difference reached significance for IP-10 (P = .01) and Mig (P = .04). Expression of RANTES, which correlated with the highest degree of significance with EBV-positive status, was most abundant in the NS subtype, which was largely due to the high levels of RANTES expression by the two EBV-positive cases in this group.

Table 3.

Levels of Chemokine mRNA Expression in Lymphoid Hyperplasia and HD Tissues

Chemokines RLH Hodgkin’s MC Hodgkin’s NSHodgkin’s NLP
IP-10  4559  174159  7888  17074 
 (x/÷1.6)  (x/÷1.17)  (x/÷2.47) (x/÷1.82)  
Mig  4648  612873  75030  168569 
 (x/÷5.8)  (x/÷1.13)  (x/÷1.82) (x/÷1.63)  
MIP-1α  6989  73063  17665  14904 
 (x/÷1.8)  (x/÷1.36)  (x/÷2.41) (x/÷1.65)  
RANTES  70104  342983  567879  92309 
 (x/÷1.6)  (x/÷1.77)  (x/÷1.39) (x/÷1.59)  
Eotaxin  24  331  25769  139 
 (x/÷3.7)  (x/÷2.49)  (x/÷3.33) (x/÷2.35)  
MDC  25263  835  199109  338 
 (x/÷1.3)  (x/÷5.11)  (x/÷1.91) (x/÷3.72) 
Chemokines RLH Hodgkin’s MC Hodgkin’s NSHodgkin’s NLP
IP-10  4559  174159  7888  17074 
 (x/÷1.6)  (x/÷1.17)  (x/÷2.47) (x/÷1.82)  
Mig  4648  612873  75030  168569 
 (x/÷5.8)  (x/÷1.13)  (x/÷1.82) (x/÷1.63)  
MIP-1α  6989  73063  17665  14904 
 (x/÷1.8)  (x/÷1.36)  (x/÷2.41) (x/÷1.65)  
RANTES  70104  342983  567879  92309 
 (x/÷1.6)  (x/÷1.77)  (x/÷1.39) (x/÷1.59)  
Eotaxin  24  331  25769  139 
 (x/÷3.7)  (x/÷2.49)  (x/÷3.33) (x/÷2.35)  
MDC  25263  835  199109  338 
 (x/÷1.3)  (x/÷5.11)  (x/÷1.91) (x/÷3.72) 

Numerical values represent geometric means of normalized pixels/disease subtype (x/÷ SEM).

Paraffin-embedded sections sequential to those used for RNA extractions were stained with a rabbit antiserum to either human IP-10 or Mig. All HD tissues studied (Table 2), representative of the MC subtype (6 cases), the NS subtype (9 cases), and the NLP subtype (5 cases) stained positively for IP-10 and Mig, albeit with variations in intensity (Fig 4). Consistent with the results of RT-PCR analysis, staining for these chemokines was generally more prominent in MC cases than in the other two histologic subtypes. Control RLH tissues generally did not stain or stained very faintly for IP-10 and Mig (Fig 4). In general, HD tissue staining for these chemokines was intracellular, the patterns of staining for IP-10 and Mig were indistinguishable, and positivity for Mig was somewhat more intense than for IP-10. The brightest cells staining for Mig and IP-10 were identified morphologically as RS and Hodgkin’s cells. In general, staining appeared to be more intense in RS cells in EBV positive versus EBV negative cases. Other cells staining less intensely for these chemokines were identified morphologically as endothelial cells lining capillary vessels, macrophages, lymphocytes, and occasionally, fibroblasts. These results document the presence of IP-10 and Mig proteins in HD tissues and identify the RS and Hodgkin’s cells as positive for these chemokines.

Fig. 4.

Immunohistochemical analysis of IP-10, Mig, and eotaxin protein expression in HD tissues: MC, NS, and NLP, and lymphoid hyperplasia. Paraffin-embedded tissue sections were stained with hematoxylin and eosin (H&E), an anti-IP–10 heteroantiserum (IP-10), an anti-Mig heteroantiserum (Mig), and an antieotaxin heteroantiserum (eotaxin). Primary antibodies were detected with biotinylated antirabbit IgG, followed by streptavidin-peroxidase complexes.

Fig. 4.

Immunohistochemical analysis of IP-10, Mig, and eotaxin protein expression in HD tissues: MC, NS, and NLP, and lymphoid hyperplasia. Paraffin-embedded tissue sections were stained with hematoxylin and eosin (H&E), an anti-IP–10 heteroantiserum (IP-10), an anti-Mig heteroantiserum (Mig), and an antieotaxin heteroantiserum (eotaxin). Primary antibodies were detected with biotinylated antirabbit IgG, followed by streptavidin-peroxidase complexes.

Close modal

As detailed above, levels of eotaxin and MDC expression in HD tissues did not correlate with evidence of tissue infection with EBV. Because eotaxin has been reported to serve as a specific chemoattractant for eosinophils, we examined whether a correlation existed between the degree of tissue infiltration with eosinophils and levels of eotaxin expression in HD tissues. Levels of eosinophil infiltration were estimated without knowledge of the results of PCR analysis by scoring histology slides stained with hematoxylin/eosin. A highly significant direct correlation (P = .0038) was identified between the extent of eosinophil infiltration (defined on the basis of the mean number of eosinophils/high powered field) and levels of HD tissue expression of eotaxin (Fig 5). By contrast, no significant direct correlation was identified between tissue eosinophilia and levels of expression of IP-10, Mig, MIP-1α, and RANTES. As a group, the NS subtype displayed both the highest levels of tissue eosinophilia and of eotaxin expression when compared with the other subtypes (Table 3). Although levels of MDC expression in HD tissues, as a group, were found not to differ significantly from those of RLH tissues (P = .7, Fig 2), within HD subtypes, MDC expression was significantly higher in the NS subtype as compared with the other subtypes (P = .002, Table 3).

Fig. 5.

Correlation of eotaxin mRNA expression and grade of tissue eosinophilia in HD. Tissue eosinophilia was quantified by counting the mean number of eosinophils/high powered field (at least 20 high powered fields were examined in each specimen). Tissue samples were classified as having 0 eosinophils/high powered field; 1 to 25 eosinophils/high powered field; or >25 eosinophils/high powered field.

Fig. 5.

Correlation of eotaxin mRNA expression and grade of tissue eosinophilia in HD. Tissue eosinophilia was quantified by counting the mean number of eosinophils/high powered field (at least 20 high powered fields were examined in each specimen). Tissue samples were classified as having 0 eosinophils/high powered field; 1 to 25 eosinophils/high powered field; or >25 eosinophils/high powered field.

Close modal

Paraffin-embedded sections sequential to those used for RNA extractions were stained with a rabbit antiserum to eotaxin, including HD tissues representative of the MC (5 cases), NS (7 cases), and NLP (4 cases) subtypes, as well as control RLH tissues (9 cases). Consistent with RT-PCR results, eotaxin protein expression was generally more intense in the NS subtype (3 cases) compared with the other subtypes and control RLH. Cells staining for eotaxin were identified morphologically as RS and Hodgkin’s cells, fibroblasts, macrophages, lymphocytes, and medial smooth muscle cells of medium and large-sized vessels (Fig 4).

In the present study, we have explored a potential role for chemokines in the pathobiology of HD. Overall, HD tissues displayed higher levels of expression of the chemokines IP-10, Mig, MIP-1α, RANTES, and eotaxin, but not MDC, when compared with lymph node tissues diagnosed with RLH. Within HD tissues, we found major differences in chemokine gene expression among the different disease subtypes. Mig and IP-10 were expressed at significantly higher levels in the MC subtype compared with the other subtypes, whereas eotaxin and MDC were expressed preferentially in the NS subtype. RANTES expression was high in both the MC and NS subtypes, and Mig was high in the NLP subtype.

On the basis of previous studies6,7 in athymic mice that had identified a pattern of chemokine response induced by EBV-infected, but not uninfected, B cells, we looked for differences of chemokine expression in EBV-positive and negative HD tissues. Similar to the situation in mice,6 7 we found levels of IP-10, Mig, and RANTES to be higher in EBV-positive than in EBV-negative HD tissues. MIP-1α expression also was significantly higher in EBV-positive than in EBV-negative HD tissues. By contrast, eotaxin and MDC expression levels were similar in HD tissues with or without evidence of EBV infection. When we analyzed the potential relationship between eotaxin expression and eosinophil infiltration, a highly significant correlation emerged, suggesting that eotaxin is a critical mediator of eosinophil recruitment in HD tissues.

Several factors have been proposed to promote eosinophil attraction, including platelet activating factors, RANTES, IL-16, MCP3, MCP4, myeloid progenitor inhibitory factors 1 and 2 (MPIF-1 and 2), hemofiltrate C-C chemokine-2 (HCC-2), secretoneurin, eotaxin, and eotaxin-2.13-23 The latter two chemokines have received considerable attention because, unlike all other factors, they appear to signal through a single receptor, CCR3, that is expressed at high levels on eosinophils and T-helper cells, but is not expressed on neutrophils or monocytes.18 24-29 This observation might explain why we observe a rich eosinophilic and T-cell inflammatory infiltrate in HD tissues where there is increased eotaxin expression.

These results suggest that, in addition to its previously recognized functions in allergic and inflammatory disorders,30-33eotaxin is likely to play an important role in promoting eosinophil recruitment to HD tissues.

Previous studies have documented production of abnormally high levels of IFN-γ and various cytokines in HD.1-4 Because some of these mediators can play an important role in regulation of chemokine production, it is not surprising that we found high level expression of certain chemokines in HD tissues. Expression of IP-10 and Mig that are IFN-γ inducible chemokines is consistent with the previously recognized abundance of IFN-γ in HD.1,34,35 Expression of eotaxin, which is inducible by IL-3,17 is consistent with increased IL-3 levels reported in this malignancy (data not shown).4 However, predictions on chemokine expression are difficult, particularly in situations, such as HD, in which abnormal or unbalanced production involves so many cytokines that participate in complex networks.

The CXC chemokines, IP-10 and Mig, share a common receptor, CXCR3, which is expressed on T and NK cells, but is undetectable on monocyte/macrophages, neutrophils, B cells, and endothelial cells.36,37 Accordingly, IP-10 and Mig are chemoattractants for T and NK cells.37 Based on this information, one might expect greater levels of infiltration with T, NK, and other cells in EBV-positive than in EBV-negative HD tissues. However, previous studies have failed to identify histologic and immunohistochemical differences between EBV-positive and EBV-negative HD, except those expected from the different frequencies of EBV infection in the MC (60% to 70%), NS (about 40%), and NLP (usually EBV negative) subtypes. Of note, one study suggested that EBV-positivity or latent membrane protein 1 (LMP1) protein expression was a favorable prognostic factor in HD,38 a result that is consistent with the known antitumor effects of IP-10 and Mig.6,7 39 

Immunohistochemical studies localized IP-10 and Mig to Hodgkin’s and RS cells and to some surrounding inflammatory cells. We know that virtually all Hodgkin’s and RS cells are infected with EBV in virus-positive HD cases and display a type II virus latency, with expression of EBNA1 and LMP1 proteins, but not other EBV latency proteins.4,40,41 LMP1, an integral membrane protein, is emerging as a multifunctional protein that plays a critical role in EBV immortalization and is responsible for many of the phenotypic changes characteristic of EBV-immortalized cells. Because LMP-1 serves as a potent activator of the transcription factor NF-κB,42-44it may promote the production of a variety of cytokines and chemokines, including IP-10, Mig, RANTES, and MIP1-α, genes that contain κB elements. In athymic mice, we found that LMP1 expression alone in EBV-negative Burkitt cells induced a host response that included production of murine IP-10 and Mig.39 Thus, LMP1 is likely to represent an important inducer of IP-10 and Mig expression within the EBV-infected Hodgkin’s and RS cells, as well as by other inflammatory cells reactive to the neoplastic cells.

Expression of MDC mRNA has been shown to be enhanced by IL-1α, TNF-α, and lipopolysaccharide (LPS)45 and can promote chemoattraction of monocytes, monocyte-derived dendritic cells, and NK cells acting through the CCR4 receptor.46 It is intriguing that MDC is expressed at markedly high levels in the NS subtype of HD, and this result will require further investigation.

The abundance of inflammatory cells surrounding few neoplastic cells and the associated abnormal or unbalanced production of cytokines have been interpreted as reflective of an intense, but ineffective, antitumor response.4 HD patients display a variety of T-cell immune defects, including the absence of CD8-positive T cells surrounding the neoplastic cells and a failure to develop LMP-1–specific cytotoxic cells that may allow RS and Hodgkin’s cells to escape immune destruction.4 Nevertheless, patients with HD do not develop systemic EBV-positive lymphoproliferative disease, as may be observed in cases of congenital or acquired severe T-cell immunodeficiency. One interesting feature of the T cells infiltrating the neoplastic cells in HD is their failure to express the activation marker CD26 molecule that possesses dipeptidyl peptidase IV activity.4 Recently, it was found that chemokines can serve as substrates for CD26.47 Once truncated by CD26, chemokines can display functional differences from the native molecules, suggesting that CD26 processing may represent an important physiological mechanism for regulation of chemokine function.47 

Thus, in addition to other previously reported immune abnormalities, the results presented here provide evidence for the occurrence of broad chemokine expression in HD tissues that could explain some of the characteristic cellular infiltrates in the different subtypes. Persistent chemokine stimulation by EBV and other stimuli combined with a potentially defective chemokine processing mechanism may contribute to a stagnant antitumor response in HD.

We thank Dr Barry Cherney, Jared Berkowitz, and Karen Jones for laboratory assistance; Andrew Weiss for technical assistance with EBV in situ hybridizations; and Dr Laszlo Krenacs, Dr Xu Yao, and Dr Leticia Quintanilla-Fend for technical advice and assistance with immunohistochemical analyses.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. section 1734 solely to indicate this fact.

1
Gruss
H
Herrmann
F
Drexler
H
Hodgkin’s disease: A cytokine-producing tumor—A review.
Crit Rev Oncog
5
1994
473
2
Gorschluter
M
Bohlen
H
Hasenclever
D
Diehl
V
Tesch
H
Serum cytokine levels correlate with clinical parameters in Hodgkin’s disease.
Ann Oncol
6
1995
477
3
Foss
H
Herbst
H
Gottstein
S
Demel
G
Araujo
I
Stein
H
Interleukin-8 in Hodgkin’s disease: Preferential expression by reactive cells and association with neutrophil density.
Am J Pathol
148
1996
1229
4
Gruss
H-J
Pinto
A
Duyster
J
Poppema
S
Herrmann
F
Hodgkin’s disease: A tumor with disturbed immunological pathways.
Immunol Today
18
1997
156
5
Angiolillo
A
Sgadari
C
Taub
D
Liao
F
Farber
J
Maheshwari
S
Kleinman
H
Reaman
G
Tosato
G
Human Interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo.
J Exp Med
182
1995
155
6
Sgadari
C
Angiolillo
A
Cherney
B
Pike
S
Farber
J
Koniaris
L
Vanguri
P
Burd
P
Sheikh
N
Gupta
G
Teruya-Feldstein
J
Tosato
G
Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo.
Proc Natl Acad Sci USA
93
1996
13791
7
Sgadari
C
Farber
J
Angiolillo
A
Liao
F
Teruya-Feldstein
J
Burd
P
Yao
L
Gupta
G
Kanegane
C
Tosato
G
Mig, the monokine induced by interferon-γ, promotes tumor necrosis in vivo.
Blood
89
1997
2635
8
Teruya-Feldstein
J
Jaffe
ES
Burd
PR
Kanegane
H
Kingma
DW
Wilson
WH
Longo
DL
Tosato
G
The role of Mig, the monokine induced by interferon-γ, and IP-10, the interferon-γ inducible protein 10, in tissue necrosis and vascular damage associated with Epstein-Barr virus-positive lymphoproliferative disease.
Blood
90
1997
4099
9
Taub
D
Oppenheim
J
Chemokines, inflammation, and the immune system.
Ther Immunol
1
1994
229
10
Harris
N
Jaffe
E
Stein
H
Banks
P
Chan
J
Cleary
M
Delsol
G
De Wolf-Peeters
C
Falini
B
Gatter
K
Grogan
T
Isaacson
P
Knowles
D
Mason
D
Muller-Hermelink
H-K
Pileri
S
Piris
M
Ralfkiaer
E
Warnke
R
A Revised European-American Classification of Lymphoid Neoplasms: A proposal from the International Lymphoma Study Group.
Blood
84
1994
1361
11
Kingma
D
Weiss
W
Jaffe
E
Kumar
S
Frekko
K
Raffeld
M
EBV LMP-1 oncogene deletions: Correlations with malignancy in EBV-associated lymphoproliferative disorders and malignant lymphomas.
Blood
88
1996
242
12
Pallesen
G
Hamilton-Dutoit
S
Rowe
M
Young
L
Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin’s disease.
Lancet
337
1991
320
13
Ponath
PD
Qin
S
Ringler
DJ
Clark-Lewis
I
Wang
J
Kassam
N
Smith
H
Shi
X
Gonzalo
J
Newman
W
Gutierrez-Ramos
J
Mackay
CR
Cloning of the human eosinophil chemoattractant, eotaxin.
J Clin Invest
97
1996
604
14
Wardlaw
A
Moqbel
R
Cromwell
O
Kay
A
Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils.
J Clin Invest
78
1986
1701
15
Rot
A
Krieger
M
Brunner
T
Bischoff
S
Schall
T
Dahinden
C
RANTES and macrophage inflammatory protein 1α induce the migration and activation of normal human eosinophil granulocytes.
J Exp Med
176
1992
1489
16
Dahinden
C
Geiser
T
Brunner
T
von Tscharner
V
Caput
D
Ferrara
P
Minty
A
Baggiolini
M
Monocyte chemotactic protein 3 is a most effective basophil-and eosinophil-activating chemokine.
J Exp Med
179
1994
751
17
Garcia-Zepeda
EA
Rothenberg
ME
Ownbey
RT
Celestin
J
Leder
P
Luster
AD
Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia.
Nat Med
2
1996
449
18
Forssmann
U
Uguccioni
M
Loetscher
P
Dahinden
C
Langen
H
Thelen
M
Baggiolini
M
Eotaxin-2, a novel CC chemokine that is selective for the chemokine receptor CCR3, and acts like eotaxin on human eosinophil and basophil leukocytes.
J Exp Med
185
1997
2171
19
Uguccioni
M
Loetscher
P
Forssmann
U
Dewald
B
Li
H
Lima
S
Li
Y
Kreider
B
Garotta
G
Thelen
M
Baggiolini
M
Monocyte chemotactic protein 4 (MCP-4), a novel structural and functional analogue of MCP-3 and eotaxin.
J Exp Med
183
1996
2379
20
Patel
VP
Kreider
BL
Li
Y
Li
H
Leung
K
Salcedo
T
Nardelli
B
Pippalla
V
Gentz
S
Thotakura
R
Parmelee
D
Gentz
R
Garotta
G
Molecular and functional characterization of two novel human C-C chemokines as inhibitors of two distinct classes of myeloid progenitors.
J Exp Med
185
1997
1163
21
Dunzendorfer
S
Schratzberger
P
Reinisch
N
Kahler
CM
Wiedermann
CJ
Secretoneurin, a novel neuropeptide, is a potent chemoattractant for human eosinophils.
Blood
91
1998
1527
22
Pardigol
A
Forssmann
U
Zucht
HD
Loetscher
P
Schulz-Knappe
P
Baggiolini
M
Forssmann
WG
Magert
HJ
HCC-2, a human chemokine: Gene structure, expression pattern, and biological activity.
Proc Natl Acad Sci USA
95
1998
6308
23
Palframan
RT
Collins
PD
Williams
TJ
Rankin
SM
Eotaxin induces a rapid release of eosinophils and their progenitors from the bone marrow.
Blood
91
1998
2240
24
Daugherty
BL
Siciliano
SJ
DeMartino
JA
Malkowitz
L
Sirotina
A
Springer
MS
Cloning, expression, and characterization of the human eosinophil eotaxin receptor.
J Exp Med
183
1996
2349
25
Ponath
PD
Qin
S
Post
TW
Wang
J
Wu
L
Gerard
NP
Newman
W
Gerard
C
Mackay
CR
Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils.
J Exp Med
183
1996
2347
26
Teixeira
MM
Wells
TN
Lukacs
NW
Proudfoot
AE
Kunkel
SL
Williams
TJ
Hellewell
PG
Chemokine-induced eosinophil recruitment. Evidence of a role for endogenous eotaxin in an in vivo allergy model in mouse skin.
J Clin Invest
100
1997
1657
27
White
JR
Imburgia
C
Dul
E
Appelbaum
E
O’Donnell
K
O’Shannessy
DJ
Brawner
M
Fornwald
J
Adamou
J
Elshourbagy
NA
Kaiser
K
Foley
JJ
Schmidt
DB
Johanson
K
Macphee
C
Moores
K
McNulty
D
Scott
GF
Schleimer
RP
Sarau
HM
Cloning and functional characterization of a novel human CC chemokine that binds to the CCR3 receptor and activates human eosinophils.
J Leukoc Biol
62
1997
667
28
Sallusto
F
Mackay
C
Lanzavecchia
A
Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells.
Science
277
1997
2005
29
Gerber
BO
Zanni
MP
Uguccioni
M
Loetscher
M
Mackay
CR
Pichler
WJ
Yawalkar
N
Baggiolini
M
Moser
B
Functional expression of the eotaxin receptor CCR3 in T lymphocytes co-localizing with eosinophils.
Curr Biol
7
1997
836
30
Mochizuki
M
Bartels
J
Mallet
AI
Christophers
E
Schroder
JM
IL-4 induces eotaxin: A possible mechanism of selective eosinophil recruitment in helminth infection and atopy.
J Immunol
160
1998
60
31
Peled
A
Gonzalo
JA
Lloyd
C
Gutierrez-Ramos
JC
The chemotactic cytokine eotaxin acts as a granulocyte-macrophage colony-stimulating factor during lung inflammation.
Blood
91
1998
1909
32
Ying
S
Robinson
DS
Meng
Q
Rottman
J
Kennedy
R
Ringler
DJ
Mackay
CR
Daugherty
BL
Springer
MS
Durham
SR
Williams
TJ
Kay
AB
Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells.
Eur J Immunol
27
1997
3507
33
Matthews
AN
Friend
DS
Zimmermann
N
Sarafi
MN
Luster
AD
Pearlman
E
Wert
SE
Rothenberg
ME
Eotaxin is required for the baseline level of tissue eosinophils.
Proc Natl Acad Sci USA
95
1998
6273
34
Hsu
S
Hsu
P
Lack of effect of colony-stimulating factors, interleukins, interferons, and tumor necrosis factor on the growth and differentiation of cultured Reed-Sternberg cells: Comparison with effects of phorbol ester and retinoic acid.
Am J Pathol
136
1990
181
35
Merz
H
Fliedner
A
Orscheschek
K
Binder
T
Sebald
W
Muller-Hermelink
H
Feller
A
Cytokine expression in T-cell lymphomas and Hodgkin’s disease: Its possible implication in autocrine or paracrine production as a potential basis for neoplastic growth.
Am J Pathol
139
1991
1173
36
Loetscher
M
Gerber
B
Loetscher
P
Jones
S
Piali
L
Clark-Lewis
I
Baggiolini
M
Moser
B
Chemokine receptor specific for IP10 and Mig: Structure, function, and expression in activated T-lymphocytes.
J Exp Med
184
1996
963
37
Liao
F
Rabin
R
Yannelli
J
Koniaris
L
Vanguri
P
Farber
J
Human Mig chemokine: Biochemical and functional characterization.
J Exp Med
182
1995
1301
38
Morente
M
Piris
M
Abraira
V
Acevedo
A
Aguilera
B
Bellas
C
Fraga
M
Garcia-Del-Moral
R
Gomez-Marcos
F
Menarguez
J
Oliva
H
Sanchez-Beato
M
Montalban
C
Adverse clinical outcome in Hodgkin’s disease is associated with loss of retinoblastoma protein expression, high Ki67 proliferation index, and absence of Epstein-Barr virus-latent membrane protein 1 expression.
Blood
6
1997
2429
39
Cherney
B
Sgadari
C
Kanegane
C
Wang
F
Tosato
G
Expression of the Epstein-Barr virus protein LMP1 mediates tumor regression in vivo.
Blood
91
1998
2491
40
Haluska
F
Brufsky
A
Canellos
G
The cellular biology of the Reed-Sternberg cell.
Blood
84
1994
1005
41
Klein
G
Epstein-Barr virus-carrying cells in Hodgkin’s disease.
Blood
80
1992
299
42
Rothenberger
S
Bachmann
E
Berger
C
McQuain
C
Odermatt
BF
Knecht
H
Natural 30 base pair and 69 base pair deletion variants of the LMP1 oncogene do stimulate NF-kappa B-mediated transcription.
Oncogene
14
1997
2123
43
Devergne
O
Hatzivassiliou
E
Izumi
KM
Kaye
KM
Kleijnen
MF
Kieff
E
Mosialos
G
Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: Role in NF-kappa B activation.
Mol Cell Biol
16
1996
7098
44
Huen
DS
Henderson
SA
Croom-Carter
D
Rowe
M
The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain.
Oncogene
10
1995
549
45
Rodenburg
RJ
Brinkhuis
RF
Peek
R
Westphal
JR
Van Den Hoogen
FH
van Venrooij
WJ
van de Putte
LB
Expression of macrophage-derived chemokine (MDC) mRNA in macrophages is enhanced by interleukin-1 beta, tumor necrosis factor alpha, and lipopolysaccharide.
J Leukoc Biol
63
1998
606
46
Godiska
R
Chantry
D
Raport
CJ
Sozzani
S
Allavena
P
Leviten
D
Mantovani
A
Gray
PW
Human macrophage-derived chemokine (MDC), a novel chemoattractant for monocytes, monocyte-derived dendritic cells, and natural killer cells.
J Exp Med
185
1997
1595
47
Oravecz
T
Pall
M
Roderiquez
G
Gorrell
M
Ditto
M
Nguyen
N
Boykins
R
Unsworth
E
Norcross
M
Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell expressed and secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage.
J Exp Med
186
1997
1865

Author notes

Address reprint requests to Julie Teruya-Feldstein, MD, Hematopathology Section, Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bldg 10, Room 2A33, 10 Center Dr, MSC 1500, Bethesda, MD 20892-1500; e-mail: jtf@helix.nih.gov.

Sign in via your Institution